1 / 33

Perchlorate The State of the Science Human Studies

Perchlorate The State of the Science Human Studies. Offie Porat Soldin, Ph.D. Consultants in Epidemiology and Occupational Health, Inc. Washington, D.C. 12-12- 2001. Thyroid NIS Perchlorate Exposure ranges. Occupational Environmental Neonatal Pediatric Adult Cancer Clinical studies.

zed
Télécharger la présentation

Perchlorate The State of the Science Human Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Perchlorate The State of the Science Human Studies Offie Porat Soldin, Ph.D. Consultants in Epidemiology and Occupational Health, Inc. Washington, D.C. 12-12- 2001

  2. Thyroid NIS Perchlorate Exposure ranges Occupational Environmental Neonatal Pediatric Adult Cancer Clinical studies Outline

  3. Perchlorate (ClO4-) ionCharacteristics • A halogen Oxyanion:

  4. Perchlorate (ClO4-) ion properties • High chemical stability. The reduction of Cl from a +7 oxidation state to –1 as a chloride requires energy or a catalyst and does not occur spontaneously • Hygroscopic. Highly water soluble • (AP is 20g/100g solution @ 25oC) • Exceedingly mobile in aqueous systems • Density nearly twice that of water • Can persist for decades due to kinetic barriers to its reactivity with other constituents

  5. The Sodium-Iodide Symporter (NIS) • An intramembrane protein of 65kD • Co-transports iodide (I-) with two sodium (Na+) ions against an electrochemical gradient • Iodine thyroid/plasma gradient equals 25: 1 to 500: 1 • Controls the uptake of iodine by the thyroid

  6. The Sodium-Iodide Symporter

  7. Iodine

  8. Effects of Iodine Deficiency Disorders

  9. Pregnancy and Thyroid Function – The Mother • Iodine clearance by the kidney increases - increased glomerular filtration • Iodine and iodothyronines transferred to fetus • Women living in low iodine intake areas may develop iodine deficiency and enlarged thyroid • The hypothalamic-pituitary-thyroid axis functions normally in pregnant women with adequate iodine

  10. Thyroid Adequacy

  11. Pregnancy and Thyroid Function – Fetus / Neonate I • Maternal hypothyroidism can be associated with neonatal defects (mental deficiency/ neurological defects/ low or normal IQs) • If infants have low T3 and T4 levels and elevated TSH levels, early appropriate treatment results in a normal intellect

  12. Pregnancy and Thyroid Function – Fetus / Neonate II • NIS presence in mammary glands leads to secretion of iodine in milk, which is probably important for thyroid function in neonates • Prolactin stimulates NIS production which is inhibited by most anti-thyroidal agents, but not by perchlorate

  13. ClO4- in water - Detection • 1997 – Ion chromatography, assay sensitivity improved from 400ppb to 4 μg/L (4 ppb) • Public water supplies found to contain perchlorate ions: S California - 5-8 ppb; S Nevada - 5-24 ppb • Method modified for ClO4- detection in urine (LOD 500 ppb) and serum (LOD 50 ppb) • Electrospray ionization (ESI/MS/MS) (LOD 0.5 ppb) Less signal suppression by nitrate, bicarbonate and sulfate

  14. Perchlorate Potential ExposurePotential Risk • Pathologic • Therapeutic • Pharmacology • Occupational • Environmental • Neonatal • Pediatric • Adult • Cancer

  15. Study Daily Dosage (mg/day) Body Weight Adjusted Daily Dosage (mg/kg/day) Length of Treatment for each case Effects Hobson 1961 800 600 11 9 14 weeks 20 weeks Fatal aplastic anemia Johnson & Moore 1961 1000 600 14 9 3 months 1 month  Fatal aplastic anemia Fawcett & Clark 1961 600 400 9 6 5 months 1-2 months  Fatal aplastic anemia Krevans et al. 1962 800 600 450 11 9 6 2 weeks 2 months 2 months  Fatal aplastic anemia Gjemdal 1963 600 400 9 6 3 months 1 month  Fatal aplastic anemia Barzilai and Sheinfeld 1966 1000 14 2 months Fatal aplastic anemia 1000 14 Few Months Fatal agranulocytosis Reported Deaths from Bone Marrow Toxicity among Perchlorate-treated Thyrotoxicosis Patients

  16. Therapeutic use of ClO4-

  17. Perchlorate Pharmacology I • Pharmacology • rapidly absorbed • excreted intact in the urine • half-life: 5-8 hr (humans) • 95% recovered in urine over 72 hr • similar ionic size to iodide • competitive inhibitor of NIS

  18. Perchlorate Pharmacology II • May not be translocated into the thyroid cell • Ki is estimated as 0.4-24 μM • May inhibit iodide accumulation → goiter1 and lead to hypothyroidism if iodine intake low < 50-150 μg/day • May inhibit organic binding of iodine by affecting thyroid peroxidase (not proven) 1 Toxic multinodular goiter (Plummer’s disease) refers to an enlarged multinodular goiter commonly found in areas of iodine deficiency in which patients with long-standing non-toxic goiter develop thyrotoxicosis

  19. Perchlorate Diagnostic Use • The perchlorate discharge test - detect iodide organification defects (1000 mg) • Pertechnetate (Tc 99m) radiological studies to image brain, blood pool, localize the placenta. Pretreatment: 200-400 mg ClO4- minimizes pertechnetate in thyroid, salivary glands and choroid plexus • Perchlorate is used to block the gastric uptake of Tc 99m in the investigation of GI bleeding

  20. Perchlorate Epidemiological StudiesOccupational Exposure • To determine exposure levels and potential health effects need to estimate a safe working level of perchlorate • Much higher than environmental • Exposure: inhalation, ingestion, or dermal contact • Significant systemic absorption likely because of the high aqueous solubility at body temperature • USA: No occupational standard for perchlorate • OSHA regulates perchlorate as a nuisance dust (limit of 15 mg/m3 (time-weighted average) • Safety concerns – it has explosive potential

  21. Gibbs et al. (1998) Nevada Cumulative exposure Average lifetime dose: 38 mg/kg No adverse effects on thyroid Shift exposure Inhaled dose: 0.2-436 g/kg (ave 36g/kg) Lamm et al. (1999) Utah Cross sectional Individual exposure Pre- post-shift urine Group exposure 3 exposures & control group Urine: 0.9 – 34 mg/shift (LOD=500 ppb) Serum: 110 – 1600 ppb (LOD 50 ppb) No adverse effects on thyroid function 0.01-34 mg/day Occupational Studies

  22. Perchlorate Exposure • Environmental • Neonatal • Pediatric • Adult • Cancer • Clinical Studies

  23. 1. CH data – no CH increase in exposed areas 2. T4 - Las Vegas (+ ClO4-15ppb) neonates compared with Reno(-) No ClO4- effect Brechner -Arizona 3. Neonatal TSH - Las Vegas (+ ClO4-) neonates compared with Reno (-) Perchlorate exposure had no effect 4.Chile – neonatal TSH (n=9,784). (100-120 ppb compared to low exposures 5-7 and <4ppb) No differences found in TSH levels Neonatal StudiesEnvironmental exposure • Neonatal screening routine in most of the developed world • Congenital hypothyroidism (CH) treatable if caught early enough

  24. Children and adolescents at greatest risk for low I2 Crump et al. studied school-age children (n = 162) 100-120 ppb, 5-7ppb and < 4ppbClO4- in their drinking water No differences found in TSH, FT4 and goiter prevalence Pediatric StudiesEnvironmental exposure

  25. Nevada Medicaid database (1997-1998) Prevalence of thyroid diseases in areas exposed to ClO4-vs. areas unexposed The prevalence rates of thyroid diseases was no greater in areas exposed to ClO4-in drinking water Adult StudiesEnvironmental exposure

  26. Thyroid Cancer StudiesEnvironmental exposure • Risk measures of thyroid cancer • Prevalence, Mortality, Incidence • All 3 measures showed no association with ClO4-exposure • ClO4- is non-mutagenic

  27. Prospective Volunteer Studies I • 900 mg/day ClO4-for 4 wks – FT4 decreased; thyroid gland not depleted of iodine (Brabant et al. 1992) • Iodine uptake inhibition studies (Lawrence et al. 2001) • Thyroid function studies and iodine-uptake studies (prior/ during 2 wk exposure (3 mg or 10 mg ClO4-)/ 2 wks post-exposure • No effect on thyroid function studies (T4, T3, FTI, thyroid hormone binding ratio & TSH) • 10 mg/day dosage • 38 % inhibition of iodine uptake • Serum ClO4- levels: 0.6 μg/ml (6 μM) • 3 mg/day dosage • Serum ClO4- levels: below detection limit • A linear-log regression predicted a no-effect level of 2 mg/day

  28. Prospective Volunteer Studies II • Greer et al. (2000) • 35 mg/day, 7 mg/day, 1.4 mg/day and 0.5 mg/day • Found a significant inhibition of iodine uptake • A linear-log regression predicted a no-effect level of 0.5 mg/day • 0.5 mg/day had no effect on iodine uptake • The data indicated a no-effect on iodine uptake level equivalent to an environmental ClO4- drinking water level of 250 μg/L

  29. Body-Weight Adjusted Daily Dose i Effect / endpoint Daily Dose Fatal hemotoxicity (aplastic anemia) 1000 - 2000 mg 15-30 mg/kg Non-fatal hemotoxicity (blood-dyscrasias, including agranulocytosis) 600–1000mg 400 mg agranulocytosis 8.5-14 mg/kg 5.7 mg/kg Therapeutic Effect Range for Amiodarone treatment 1000 mg start followed by 100 mg 12.8 mg/kg then 1.4 mg/kg Pharmacological Effect Range (normalization of thyroid function in hyperthyroid patients) 200-1000 mg 2.8 – 14 mg/kg Calculated Safe Occupational Average (BMDL) 50 mg 0.7 mg/kg Demonstrated Safe Occupational Average ii Per shift average 2.5 mg 34 mg Per shift average 0.036 mg/kg 0.48 mg/kg No-effect level for TSH elevation in newborns iii (Environmental Level 5-25 ppb) Amount in 2L drinking water 200 μg 20 μg 2.9μg/kg 0.29μg/kg Perchlorate dose-response in humans exposed therapeutically, occupationally, in clinical studies or environmentally via drinking water i Based on a 70-kg adult ii No-effect level for tests of thyroid function in occupationally exposed iii Exposed in utero via maternal consumption of drinking water

  30. Model - Human Health and Perchlorate Exposure Ranges

  31. Summary I • Thyroid - the critical effect organ of perchlorate toxicity • Perchlorate blocks iodide uptake by NIS • Assuming intake of 2 liters of water per day, the highest known level of ClO4- in public drinking water (24 μg/L) would yield a daily exposure of less than 50 μg/day– 700 times lower than the no effect level

  32. Summary II • Absence of an observed effect on neonatal thyroid, thyroidal diseases, or thyroidal cancer in areas with ClO4- in drinking water is epidemiologically consistent with human toxicological and pharmacological observations

  33. Summary III • Methods for measurement of ClO4- in urine, serum, solid matrix, and soil will need to be standardized in order to allow a better analysis and interpretation of data

More Related